TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Maximum Tolerated Dose of Dabrafenib
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose of Trametinib
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose of Onalespib
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Dose Limiting Toxicities While Determining Maximum Tolerated Dose
Endpoint domain: Adverse events/effects
Primary endpoint: stage distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Hemocompatibility related adverse events (HRAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Successful Self-Injections Performed of All Attempts at Home on Schedule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Device Success and Freedom From Device or Procedure Related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: MR Grade ≤ 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Umbilical cord separation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Umbilical cord microbial colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of time in the therapeutic range (TTR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of Masimo Pronto 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fat-free Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tremor-related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Treatment failure at completion of antibiotic course
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EEG asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in skin conductance response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation of ventromedial prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in sFMDRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved gait pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response in oesophago-gastric cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: viraemia levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Postoperative Cognitive Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in upper limb function characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Non-serious Treatment Emergent Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Nasal Mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Olfactory Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Incidence of Adverse Events of Special Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Change in strength of alpha-beta oscillatory coupling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in beta-band oscillatory amplitude in dorsolateral pre-frontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in alpha-band oscillatory amplitude in frontal eyefields
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Quadriceps muscle volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cmax,ss of DWC202001 and DWC202002
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCτ,ss of DWC202001 and DWC202002
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of ASP8062 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of ASP8062 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in psychomotor function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Ovulation delay or inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Negative Expressed Emotion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Calibration of Prospera test for T cell-mediated rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Calibration of Prospera test for antibody-mediated rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Calibration of Prospera test for kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from baseline in serum concentrations of phosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in corrected serum concentrations of calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in serum concentrations of intact parathyroid hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Coronary Artery Calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Annualised rate of breakthrough bleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Neutralizing Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with amyloid deposits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour Worst Abdominal Pain Scores (WAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of vorinostat and azacitidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Precision of the estimated dose-response curve based on induction of lytically replicated viral particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of chair stands in 30 seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnetic activity of smooth muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Cardiovascular Collapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reaction time on the TAP computerized battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of errors on the TAP computerized battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time of recognition of an arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time of diagnosis of arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to treatment initiation of arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of pulmonary arterial hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Glycosylated Hemoglobin (HbA1c) (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: Change in E' on TDI Echo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in Drug Dose or Discontinuation of Study Drug
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: toxicity of combining epirubicin and cisplatin
Endpoint domain: Adverse events/effects
Primary endpoint: daily fibrinogen level >4 g/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in pro-inflammatory and anti-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Heat Shock Response Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-vaccination increases in mycobacteria-specific Th1 responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: post-vaccination mycobacteria-specific secretory immunoglobulin A (IgA) responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients delaying and forgetting medications
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neuromuscular integrity by motor unit function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Grade 3 or 4 Neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 4 Neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Inspiratory muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Inspiratory Muscle Endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Heart Failure-related Urgent Care Visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart Failure Hospitalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Healing of perforation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of otitis media
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Patient Health Questionnaire -Adolescent version (PHQ-A)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Freezing of Gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived Goals of Care Discussions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decrease in the Pouchitis Diseases Activity Index (PDAI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in de novo lipogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Skin IL-34 mRNA expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Frequency of donor engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants with a less postoperative menstruation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Participants being a pregnant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Tendon tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Intra-abdominal Hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uterine anatomy assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chorea severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in comfort score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in swallowing ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Glabellar Line Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Bleeding on Probing (BOP) Sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characteristics of the seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Co-morbidities and impairments
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean morphine equivalents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calculated GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Double Trouble Task Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Grammatical Reasoning Test Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Odd One Out Test Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Object Reasoning Task Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Spatial Span Task Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Monkey Ladder Task Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Digit Span Task Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of samples with HbS/HbS genotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Youth externalizing behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cortisol and Catecholamine Production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Skin Barrier Repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Immune Function: Delayed Hypersensitivity to Candida(DTH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: improved targeted chronic disease outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Termination of Ventricular Fibrillation Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Freedom From Major System and Procedure Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of migraine frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colorectal cancer screening self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nasopharyngeal macrolide resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of soil transmitted helminths
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of positive cells and intensity of expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Motor recovery of the upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of burn depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Total PUCAI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area Under the Curve (AUC) for pain on passive movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kidney Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Blood levels of Coenzyme Q10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Post-dose Increases in Liver Enzyme Levels
Endpoint domain: Adverse events/effects
Primary endpoint: Reported pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of at least 2 ocular serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: diagnostic turnaround time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in renal parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in hormonal parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Coping ability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participant intention to attend IYS sessions
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: variation of N2-P2 amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year non-regrowth disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Seroprotection in Hemagglutination Inhibition (HI) Antibody Titer of >=40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Seroconversion in Hemagglutination Inhibition (HI) Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of postoperative headache
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma glycated hemoglobin A1c (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of recurrent thromboembolic
Endpoint domain: Adverse events/effects
Primary endpoint: bleeding complications incidence
Endpoint domain: Adverse events/effects
Primary endpoint: T-cell inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: socioemotional behaviour
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incident herpes zoster
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Incidence of Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: % of RIC cycles completed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants reporting RIC associated discomfort on a likert scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: COVID-19 Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expectoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak levels of lipase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak levels of amylase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak levels of protease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with serum calcium measurements ≤ 10.3 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean decrease of serum calcium of at least 0.5 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PIPP-R pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enhanced immunity against hepatitis C virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: endometriosis tumor DNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Completion of dietary intervention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Cumulative incidence of severe bleedings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cumulative incidence of thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Social Functioning Scale (SFS) Change
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Identification of Active Myocardial Ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Short-term progression to advanced liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Percentage of time in intended SpO2-interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy for severe CAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severity of IBD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal FEV1 decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Modified performance Activities Scale for Kids (ASKp) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: C-peptide area under the curve during OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Patient experience during screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Experienced at Least One Dose-limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Composite score of family planning/HTC service provision
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: pharmacokinetics of licarbazepine and its glucuronide conjugate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Risk of Fatal Coronary Event or Non-fatal MI
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of participants reporting SE cessation within 30 minutes of IP initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes